Phase 2Enrolling by invitation
Senescence in Chronic Kidney Disease
Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents
- Sponsor
- Mayo Clinic (Academic or other)
- Enrolment
- 30 planned
- Conditions
- Chronic Kidney Disease
- Interventions
- Group 2: Dasatinib; Group 2: Quercetin
- Ages
- adults, older adults
- Registry
- NCT02848131
From the registry
The study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease (CKD).
Primary outcomes
- Change in proportion of senescent cells (representing the total senescent cell burden) present